Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas

Documenti analoghi

• Dipeptidyl Peptidase‐4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus and End‐Stage Renal Disease Requiring Dialysis
  di: Tzu‐Han Lin, et al.
  Pubblicazione: (2025)
• Sodium‐Glucose Cotransporter 2 Inhibitors Use and Adverse Kidney Outcomes in Patients Receiving Contrast Media
  di: Lung‐Chih Li, et al.
  Pubblicazione: (2025)
• CD248 deficiency promotes angiotensin II‐induced aortic lesion by attenuating receptor stability in smooth muscle cells
  di: Tai‐Tzu Hsieh, et al.
  Pubblicazione: (2025)
• Synergistic drug combination screening using a nanodroplet processing platform to enhance neuroblastoma treatment in TH‐MYCN transgenic mice
  di: Yen‐Tzu Liao, et al.
  Pubblicazione: (2025)
• The hanging‐heart chip: A portable microfluidic device for high‐throughput generation of contractile embryonic stem cell‐derived cardiac spheroids
  di: Pei‐Tzu Lai, et al.
  Pubblicazione: (2024)